n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, September 21st, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Helius Medical Technologies, Inc. (HSDT)

OTC Markets, Stockhouse, MarketWatch, and InvestorsHub reported on Helius Medical Technologies, Inc. (HSDT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Helius Medical Technologies, Inc. is a medical technology company based in Newtown, Pennsylvania . Its focus is neurological wellness and it works to develop, license, and also acquire innovative non-invasive treatments designed to amplify the brain’s ability to heal itself. NeuroHabilitation is a division of Helius Medical Technologies. NeuroHabilitation is developing a unique technology as a potential treatment for neurological symptoms caused by disease or trauma. Helius Medical Technologies’ shares trade on the OTC Markets Group’s OTCQB. 

The Company’s intention is to file for U.S. Food and Drug Administration (FDA) clearance for the Portable Neuromodulation Stimulator (PoNS™). The PoNS™ device is an investigational non-invasive device designed to deliver neurostimulation by way of the tongue.

PoNS™ Therapy combines the use of the device with physical therapy. Currently, it is undergoing evaluation in a multicenter clinical trial for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI). 

In 2013, The NeuroHabilitation division signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense. This is to develop and manage clinical and regulatory activities for the PoNS™ device and CN-NINM technologies. 

NeuroHabilitation successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract supports Helius’ registrational trial investigating the safety and effectiveness of the PoNS™. The PoNS™ is undergoing study in Canada for chronic balance and gait symptoms caused by Multiple Sclerosis. 

Helius Medical Technologies announced in January 2017 that MedStar National Rehabilitation Hospital in Washington D.C. was launched as the sixth site to provide services supporting the Company’s ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild-to-moderate Traumatic Brain Injury (TBI).

Clinical trial sites in the U.S. and Canada include Oregon Health and Science University in Portland, Oregon; Montreal Neurofeedback Center in Montreal, Quebec; Orlando Regional Medical Center in Orlando, Florida; HealthTech Connex, Inc. in Surrey, British Columbia; and Virginia Commonwealth University in Richmond, Virginia.

Recently, Helius Medical Technologies and the United States Army Medical Research and Materiel Command (USAMRMC) announced that the last subject was enrolled in the registrational clinical trial to investigate the safety and effectiveness of the PoNS™ device for the rehabilitation of chronic balance deficits caused by mild-to-moderate Traumatic Brain Injury (mTBI). The intention of the trial is to serve as the foundation for Helius to submit applications for marketing clearance in the U.S., Canada, and Europe for the PoNS™ device.

Last week, Helius Medical Technologies announced that via its wholly-owned subsidiary NeuroHabilitation Corporation (NHC), it has executed an extension to its Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research and Materiel Command (USAMRMC) through 2018 and extended the deadline for commercialization of the PoNSTM Therapy to December 31, 2021. 

Helius Medical Technologies, Inc. (HSDT), closed Thursday's trading session at $2.964, down 1.20%, on 32,228 volume with 41 trades. The average volume for the last 60 days is 26,589 and the stock's 52-week low/high is $0.961/$3.118.

Sevion Therapeutics, Inc. (SVON)

TradingView, InvestorsHub, and MarketWatch reported on Sevion Therapeutics, Inc. (SVON), and we also are reporting on the Company, here at the QualityStocks Daily Newsletter.

Sevion Therapeutics, Inc. is a biopharmaceutical enterprise that discovers, develops, and acquires next-generation biologics. The Company is building and developing a portfolio of inventive therapeutics, from internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates come from many key proprietary technology platforms - cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages. Sevion Therapeutics is based in San Diego, California.

The Company has taken advantage of the above-mentioned technologies to build a pipeline of innovative product candidates. Its antibody pipeline is undergoing development from technology, which allows for the discovery of unique biologic therapies to previously inaccessible targets. This includes multispanning membrane proteins and ion channels that play a vital role in many diseases.

Sevion Therapeutics has also developed the first protein nanocage system enabling delivery of nucleic acids and other payloads to target cells. It is working together with CNA Development, LLC (an affiliate of Janssen Pharmaceuticals, Inc.) to discover antibodies utilizing Sevion’s spatially addressed library platform. The collaboration facilitated by the Johnson & Johnson Innovation center in California will include discovery of antibodies against numerous targets in several therapeutic areas.

Sevion Therapeutics and Janssen Pharmaceuticals will jointly conduct research on antibodies discovered by Sevion. Janssen Pharmaceuticals will have an option to an exclusive license to develop, manufacture, and commercialize candidates resulting from the collaboration.

Regarding SVN-001 development, Sevion’s humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action, which has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro.

Sevion Therapeutics also has its SVN-002. This is a unique antibody against an oncology target that holds the potential to considerably impact highly metastatic tumors that are resistant to anti-VEGF treatments.

Regarding Chimerasome Nanocages, the basis of Sevion’s Chimerasome technology is on a single protein that can be assembled to form a spherical protein nanocage encapsulating drugs or nucleic acid therapeutics. The Chimerasome can be coupled to antibodies or peptides externally, enabling highly-specific cellular targeting of the payload.

Sevion has its SVN-003 product in its Chimerasome Pipeline. This is a chimerasome/insulin product that preferentially delivers insulin to the liver. SVN-003 has extremely potent glucose regulation properties in animal models.

This past June, Sevion Therapeutics and Eloxx Pharmaceuticals Ltd. announced the signing of a definitive agreement on May 31, 2017 for an acquisition transaction. With this agreement, Eloxx Pharmaceuticals will become a wholly-owned subsidiary of Sevion Therapeutics. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals, Inc. It intends to apply to have its shares listed for trading on NASDAQ. Eloxx Pharmaceuticals is a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations.

This month, Sevion Therapeutics and Eloxx Pharmaceuticals announced the expansion of its Development Team with the appointments of Colin Scott, M.D., as Medical Director who will report directly to Pedro Huertas, M.D., Ph.D., the Company's Chief Medical Officer; and Neal Sharpe, M.D., as Senior Director of Toxicology. The Company also announced that it transferred its operations headquarters from Rehovot, Israel to Boston, Massachusetts.

Sevion Therapeutics, Inc. (SVON), closed Thursday's trading session at $0.2698, up 7.92%, on 63,700 volume with 5 trades. The average volume for the last 60 days is 76,551 and the stock's 52-week low/high is $0.11/$0.38.

Blue Sphere Corp. (BLSP)

DreamTeamNetwork, MyBestStockAlerts, OTPicks, Penny Stock General, PennyStocks24, OTC Stock Review, Fast Money Alerts, Stock Shock and Awe, PremiereStockAlerts, and SmallCapVoice reported previously on Blue Sphere Corp. (BLSP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Blue Sphere Corp. is an international Independent Power Producer (IPP). The OTCQB-listed Company is working to become a key player in the global waste-to-energy and renewable energy markets.  It has a business plan that fits the changing regulatory standards for waste and energy.  A clean-tech waste-to-energy producer, Blue Sphere’s principal business model is BOO (Build-Own-Operate): long-term energy agreements are executed with electric companies in advance of projects. Blue Sphere is based in Charlotte, North Carolina. The Company has operations in the United States, Israel, and Europe.  

A waste-to-energy project integrator, Blue Sphere is performing waste-to-energy projects in the U.S. and Italy. It is pursuing a strategy to work in association with landfill owners to convert harmful methane gas emissions from landfills into electricity. The process is established on readily available technology already being used in different parts of the U.S. and other regions worldwide. 

Blue Sphere has its Charlotte, North Carolina Waste to Energy Anaerobic Digester 5.2 MW Plant. In Johnston, Rhode Island, it has its Waste to Energy Anaerobic Digester 3.2 MW Plant.  

Blue Sphere, via its wholly-owned subsidiaries, completed the acquisition of four operating biogas facilities in Italy in December of 2015. This represents a significant milestone in its history. Blue Sphere acquired 100 percent of the stock of Agricerere, S.R.L., Agrielektra, S.r.L., Agrisorse, S.r.L. and Gefa, S.r.L. 

Individually, each fully operational facility produces one megawatt of electricity per hour, which sells to Gestore del Servizi Energetici GSE, S.p.A., a state owned company, which promotes and supports renewable energy sources in Italy, under a Power Purchase Agreement (PPA) that runs through December 31, 2027. 

On December 8, 2016, the Netherlands Enterprise Agency awarded the Company's wholly owned subsidiary, Bluesphere Brabent B.V., a grant to sell renewable gas on a per MWg basis to Rijksdienst voor Ondernemend Nederland (RVO) under the Renewable Energy Production Incentive Scheme or "SDE."

Blue Sphere Corp. (BLSP), closed Thursday's trading session at $2.162, even for the day, on 3 volume with 1 trade. The average volume for the last 60 days is 3,077 and the stock's 52-week low/high is $2.05/$10.92.

Humanigen, Inc. (HGEN)

InvestorsHub, OTC Markets, AmigoBulls, Barchart, TradingView, Investopedia, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Humanigen, Inc. concentrates on advancing medicines for patients with neglected and rare diseases via innovative, accelerated business models. Lead compounds in the Company’s portfolio include benznidazole, and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Humanigen has its headquarters in Brisbane, California. The Company lists on the OTC Markets Group’s OTCQB.

Benznidazole is for the potential treatment of Chagas disease in the United States. Chagas disease is a parasitic infection caused by a protozoan organism named Trypanosoma cruzi, which affects millions of people mainly in rural areas of Mexico, Central and South America.

Lenzilumab has potential for treatment of various rare diseases. This includes hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that propels the growth of certain hematologic malignancies.

Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created utilizing Humanigen's proprietary Humaneered® technology.

In early August, Humanigen announced that it completed enrolment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is an important part of its planned New Drug Application (NDA) package to the U.S. Food and Drug Administration (FDA) in the 505(b)(2) development program for benznidazole as a potential treatment for Chagas disease. The study’s primary aim is to characterize the pharmacokinetic profile of benznidazole.

In early August, Humanigen announced it appointed Mr. Greg Jester as the Company’s Chief Financial Officer (CFO), effective September 5, 2017. Mr. Jester brings over 20 years of financial, operational management, as well as entrepreneurial experience in the life sciences industry.

He will be responsible for further strengthening Humanigen’s financial foundation to facilitate the Company’s next growth phase. Most recently, Mr. Jester served as Vice President, Finance, for Tris Pharma. 

Humanigen, Inc. (HGEN), closed Thursday's trading session at $0.38, even for the day, on 5,920 volume with 6 trades. The average volume for the last 60 days is 34,712 and the stock's 52-week low/high is $0.2262/$4.75.

K92 Mining, Inc. (KNTNF)

Stockhouse, MarketWatch, InvestorsHub, Barchart, OTC Markets, Morningstar, GuruFocus, Marketwired, TradeKing, Investors Hangout, Future Money Trends, and Resource Stock Digest reported on K92 Mining, Inc. (KNTNF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

K92 Mining, Inc. engages in the exploration and development of mineral deposits in Papua New Guinea. The Company has started gold production from the Irumafimpa Gold Deposit that together with the Kora Gold Deposit is part of its Kainantu Gold Project situated in the Eastern Highlands province of Papua New Guinea. Listed on the OTC Markets Group’s OTCQB, K92 Mining is headquartered in Vancouver, British Columbia.

Kainantu highlights include existing infrastructure. This includes underground mine development, a mill processing facility, staff housing, a licensed tailings pond, office space, paved access roads, and a reliable hydro supply via a dedicated power line. The Kainantu property encompasses a total area of roughly 410km2.

Kainantu highlights also include USD $41.3 million invested in exploration drilling and definition drilling. The current resource estimate is based on 78,935m of drilling by way of 767 drill holes. Additionally, the Process Mill has successfully treated the initial batch of underground ore delivered from Irumafimpa, with concentrate now produced; and there is a significant opportunity to expand known zones of mineralization, and for the discovery of new ore bodies.

Furthermore, Gold production at Irumafimpa is targeted to ramp to steady state operations, reaching an annualized production rate of 52,000 Au per annum, over the coming months.

Recently, K92 Mining announced it intersected what it interprets as the Kora Vein system in a cross cut from the modified Kora exploration drive. The intersection was predicted at this location and consists of a strongly sulphide (bornite, chalcopyrite and pyrite) mineralized quartz vein around 2.7 meters wide.

Channel sampling of the north and south faces of the vein system exposed in the cross cut returned an average of 9.89 g/t Au, 46 g/t Ag and 2.44 percent Cu over a true width of 2.7 meters. K92 Mining has started mining an initial 2,000 tonne bulk sample from the interpreted Kora Vein.

K92 Mining, Inc. (KNTNF), closed Thursday's trading session at $0.35, down 0.85%, on 106,709 volume with 37 trades. The average volume for the last 60 days is 106,117 and the stock's 52-week low/high is $0.34/$1.22.

graphic

The QualityStocks
Company Corner

graphic
graphic

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.347, off by 0.86%, on 398,731 volume with 181 trades. The stock’s average daily volume over the past 60 days is 347,964, and its 52-week low/high is $0.073/$0.72.

InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Added to CSE25 Index

InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media

InMed Retains Consultant Ben Paterson for Biosynthesis Development

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7184, off by 2.38%, on 172,364 volume with 151 trades. The stock’s average daily volume over the past 60 days is 113,310 and its 52-week low/high is $0.6171/$0.90.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ABcann Global (TSXV: ABCN) (OTCQB: ABCCF), a client of NNW that is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. The publication, titled, "What it Takes to Thrive in Canada's Multi-Billion-Dollar Marijuana Industry," discusses the stand-out competitors in Canada's booming cannabis industry. To view the full publication, visit: https://www.networknewswire.com/takes-thrive-canadas-multi-billion-dollar-marijuana-industry/

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication Discussing Leading Public Companies in the Canadian Marijuana Market

ABcann Global Enters Its Growth Phase (Plus Exclusive Interview) -- CFN Media

NetworkNewsWire Announces Publication on the Operations of Key Players in Canada's Legal Marijuana Market

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.068, up 7.09%, on 4,053,702 volume with 341 trades. The stock’s average daily volume over the past 60 days is 4,237,795, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding, Inc. Launches Storewide Discount on Diamond CBD Products to Support Recovery Efforts by Contributing 10% of Revenues over the Next 3 Days to Community Restoration Projects

PCAOB Registered CPA Firm Engaged to Initiate Audit on PotNetwork Holding, Inc.’s Recent Revenues

Mayweather vs. McGregor Event Brings Unprecedented Exposure to Diamond CBD and PotNetwork Holdings, “POTN”, as Sponsored Contenders Take the Spotlight

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.486, off by 3.38%, on 16,170 volume with 9 trades. The stock’s average daily volume over the past 60 days is 2,051, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility to Donate a Portion of ASME Profits to Hurricane Harvey Flood Victims

NetworkNewsWire Announces Publication on the Value of EdTech Leaders to the Skilled Labor Workforce

ProBility Completes Acquisition of Cranbury International

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.10, off by 10.71%, on 900 volume with 1 trade. The stock’s average daily volume over the past 60 days is 12,009 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

BUYINS.NET
(CCC) +62.12%

2.

MarketClub Analysis
(AKTX) +56.35%

3.

MarketBeat
(LSTMF) +50.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251